Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated:  3/9/2018
California Cancer Associates for Research Excellence (cCARE)
mi
from
Encinitas, CA
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated: 3/9/2018
California Cancer Associates for Research Excellence (cCARE)
mi
from
Encinitas, CA
Click here to add this to my saved trials
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated:  3/9/2018
James Berenson, MD, Inc
mi
from
West Hollywood, CA
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated: 3/9/2018
James Berenson, MD, Inc
mi
from
West Hollywood, CA
Click here to add this to my saved trials
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated:  3/9/2018
Oncology Specialists, S.C.
mi
from
Niles, IL
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated: 3/9/2018
Oncology Specialists, S.C.
mi
from
Niles, IL
Click here to add this to my saved trials
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated:  3/9/2018
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated: 3/9/2018
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated:  3/9/2018
Robert A. Moss, M.D. FACP, Inc.
mi
from
Fountain Valley, CA
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated: 3/9/2018
Robert A. Moss, M.D. FACP, Inc.
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated:  3/9/2018
cCARE Fresno
mi
from
Fresno, CA
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated: 3/9/2018
cCARE Fresno
mi
from
Fresno, CA
Click here to add this to my saved trials
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated:  3/9/2018
Comprehensive Cancer Center At Desert Regional Medical Center
mi
from
Palm Springs, CA
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated: 3/9/2018
Comprehensive Cancer Center At Desert Regional Medical Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated:  3/9/2018
Cancer Specialists of North Florida
mi
from
Fleming Island, FL
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated: 3/9/2018
Cancer Specialists of North Florida
mi
from
Fleming Island, FL
Click here to add this to my saved trials
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated:  3/9/2018
Lewis Hall Singletary Oncology Center
mi
from
Thomasville, GA
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated: 3/9/2018
Lewis Hall Singletary Oncology Center
mi
from
Thomasville, GA
Click here to add this to my saved trials
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated:  3/9/2018
Hattiesburg Clinic Hematology/Oncology
mi
from
Hattiesburg, MS
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated: 3/9/2018
Hattiesburg Clinic Hematology/Oncology
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated:  3/9/2018
Vista Oncology, Inc.
mi
from
Olympia, WA
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Enrolling
Updated: 3/9/2018
Vista Oncology, Inc.
mi
from
Olympia, WA
Click here to add this to my saved trials
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  3/9/2018
Clinical Research Facility
mi
from
Seattle, WA
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 3/9/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  3/9/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 3/9/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  3/9/2018
Clinical Research Facility
mi
from
Chicago, IL
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 3/9/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  3/9/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 3/9/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  3/9/2018
Clinical Research Facility
mi
from
Louisville, KY
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 3/9/2018
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  3/9/2018
Clinical Research Facility
mi
from
East Lansing, MI
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 3/9/2018
Clinical Research Facility
mi
from
East Lansing, MI
Click here to add this to my saved trials
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  3/9/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 3/9/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  3/9/2018
mi
from
Camperdown,
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 3/9/2018
mi
from
Camperdown,
Click here to add this to my saved trials
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  3/9/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 3/9/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated:  3/9/2018
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated: 3/9/2018
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated:  3/9/2018
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated: 3/9/2018
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated:  3/9/2018
Davis, Posteraro and Wasser, MDs, LLP
mi
from
Manchester, CT
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated: 3/9/2018
Davis, Posteraro and Wasser, MDs, LLP
mi
from
Manchester, CT
Click here to add this to my saved trials
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated:  3/9/2018
Florida Cancer Institute
mi
from
New Port Richey, FL
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated: 3/9/2018
Florida Cancer Institute
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated:  3/9/2018
John H. Stroger, Jr. Hospital of Cook County, Div. of Hematology and Oncology
mi
from
Chicago, IL
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated: 3/9/2018
John H. Stroger, Jr. Hospital of Cook County, Div. of Hematology and Oncology
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated:  3/9/2018
Cancer Care Center
mi
from
New Albany, IN
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated: 3/9/2018
Cancer Care Center
mi
from
New Albany, IN
Click here to add this to my saved trials
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated:  3/9/2018
Kansas City Cancer Center
mi
from
Kansas City, MO
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated: 3/9/2018
Kansas City Cancer Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated:  3/9/2018
Mount Sinai Hospital
mi
from
New York, NY
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated: 3/9/2018
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated:  3/9/2018
New York Presbyterian Hospital: Weill Medical College of Cornell University
mi
from
New York, NY
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated: 3/9/2018
New York Presbyterian Hospital: Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated:  3/9/2018
Emerywood Oncology and Hematology
mi
from
High Point, NC
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated: 3/9/2018
Emerywood Oncology and Hematology
mi
from
High Point, NC
Click here to add this to my saved trials
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated:  3/9/2018
Mid Ohio Oncology/Hematology, Inc., dba, The Mark H. Zangmeister Center
mi
from
Columbus, OH
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated: 3/9/2018
Mid Ohio Oncology/Hematology, Inc., dba, The Mark H. Zangmeister Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated:  3/9/2018
Capitol Comprehensive Cancer Care Clinic
mi
from
Jefferson City, MO
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
Status: Enrolling
Updated: 3/9/2018
Capitol Comprehensive Cancer Care Clinic
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
A Phase II Trial of Haplotype Mismatched Hematopoietic Stem Cell Transplantation Using Highly Purified CD34 Cells in Patients With Hematological Malignancies
Status: Enrolling
Updated:  3/12/2018
Indiana University Cancer Center
mi
from
Indianapolis, IN
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
A Phase II Trial of Haplotype Mismatched Hematopoietic Stem Cell Transplantation Using Highly Purified CD34 Cells in Patients With Hematological Malignancies
Status: Enrolling
Updated: 3/12/2018
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Rocky Mountain Cancer Center-Rose
mi
from
Denver, CO
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Rocky Mountain Cancer Center-Rose
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Cancer Center of Central Connecticut
mi
from
Southington, CT
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Cancer Center of Central Connecticut
mi
from
Southington, CT
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Mt Sinai Medical Center
mi
from
Miami Beach, FL
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Mt Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Emory University
mi
from
Atlanta, GA
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Harry and Jeannette Weinberg Cancer Center at Franklin Square Hospital
mi
from
Baltimore, MD
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Harry and Jeannette Weinberg Cancer Center at Franklin Square Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
The Mayo Clinic
mi
from
Rochester, MN
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Washington University
mi
from
Saint Louis, MO
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
New York Presbyterian Hospital Weill Cornell
mi
from
New York, NY
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
New York Presbyterian Hospital Weill Cornell
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Sarah Cannon Cancer Center
mi
from
Nashville, TN
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
W VA University Mary Babb Randolph Cancer Center
mi
from
Morgantown, WV
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
W VA University Mary Babb Randolph Cancer Center
mi
from
Morgantown, WV
Click here to add this to my saved trials
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  3/12/2018
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 3/12/2018
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Id-KLH Vaccine + T Cells
Randomized Phase II Trial of CD3/CD28 Activated Id-KLH Primed Autologous Lymphocytes in Subjects With Myeloma Undergoing Autologous Transplant
Status: Enrolling
Updated:  3/12/2018
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Id-KLH Vaccine + T Cells
Randomized Phase II Trial of CD3/CD28 Activated Id-KLH Primed Autologous Lymphocytes in Subjects With Myeloma Undergoing Autologous Transplant
Status: Enrolling
Updated: 3/12/2018
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials